The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.
Must sign the informed consent form (ICF) and be capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the ICF
Confirmed diagnosis of a R/R B-cell malignancy
Protocol-defined measurable disease
Stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
Treatment-naive B-cell malignancies
Unable to comply with the requirements of the protocol
Active leptomeningeal disease or uncontrolled, untreated brain metastasis
Any malignancy ≤ 2 years before first dose of study treatment except for the specific cancer under investigation in this study or any locally recurring cancer that has been treated curatively
8
Treatment groupsSee each treatment group below.